在稳定性冠心病中合理使用心肌灌注显像的成本效益分析  

Cost-effectiveness of the rational use of myocardial perfusion imaging in stable coronary artery disease

作　　者：杨丽红[1] 曾艳 李思进[1] Yang Lihong;Zeng Yan;Li Sijin(Department of Nuclear Medicine,First Hospital of Shanxi Medical University,Taiyuan 030001,China;SDIC Health Industry Investment Co.,Ltd.,Beijing 100032,China)

机构地区：[1]山西医科大学第一医院核医学科,太原030001 [2]国投健康产业投资有限公司,北京100032

出　　处：《中华核医学与分子影像杂志》2024年第7期436-439,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(U22A6008)。

摘　　要：我国心血管疾病死亡率较其他国家高,而在心血管疾病死亡原因中冠状动脉粥样硬化性心脏病(CAD)占首位。CAD治疗费用也高。费用的增加一方面与CAD发病率有关,另一方面也可能与不合理的诊疗方案有关。随着许多国家医疗保健成本的不断上升,诊断和治疗手段的成本效益问题变得越发重要。很多研究表明,大多数无创性检查比冠状动脉造影(CAG)具有更好的成本效益。该文主要综述心肌灌注显像(MPI)与CAG相比用于稳定性CAD的成本效益研究,并且比较了MPI与其他无创性检查的成本效益。China has the highest mortality rate from cardiovascular disease in the world and coronary artery disease(CAD)is the leading cause of death from cardiovascular disease.The cost of treatment for CAD is high,which is related to the incidence of CAD and possible irrational treatment protocols.However,with the escalating costs of healthcare in most countries,the cost-effectiveness of diagnostic and management testing is increasingly important.Many studies have shown that most non-invasive tests are more cost-effective than coronary angiography(CAG).This article reviews the cost-effectiveness of MPI compared with CAG and other non-invasive tests.

关 键 词：冠心病 心肌灌注显像 费用效益分析 发展趋势 

分 类 号：R541.4[医药卫生—心血管疾病]